Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy

<i>Background and Objectives</i>: Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) is used to treat acute ischemic stroke. Dabigatran is a reversible thrombin inhibitor approved for stroke prevention in patients with nonvalvular atrial fibrillation. In such...

Full description

Bibliographic Details
Main Authors: Ilga Kikule, Alise Baborikina, Iveta Haritoncenko, Guntis Karelis
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Medicina
Subjects:
ischemic stroke
thrombolysis
idarucizumab
dabigatran
antidote
intracerebral hematoma
Online Access:https://www.mdpi.com/1648-9144/58/10/1355

Internet

https://www.mdpi.com/1648-9144/58/10/1355

Similar Items